Detalles de la búsqueda
1.
Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a pooled analysis from two phase 2 studies.
BMC Med
; 21(1): 164, 2023 04 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-37118803
2.
Identification and validation of necroptosis-related prognostic gene signature and tumor immune microenvironment infiltration characterization in esophageal carcinoma.
BMC Gastroenterol
; 22(1): 344, 2022 Jul 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35840882
3.
LPAR2 correlated with different prognosis and immune cell infiltration in head and neck squamous cell carcinoma and kidney renal clear cell carcinoma.
Hereditas
; 159(1): 16, 2022 Mar 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35241179
4.
Identification of a necroptosis-related prognostic gene signature associated with tumor immune microenvironment in cervical carcinoma and experimental verification.
World J Surg Oncol
; 20(1): 342, 2022 Oct 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-36253777
5.
Influence of Dynamic and Static Obstructive Renal Artery on Early Prognosis in Stanford Type A Aortic Dissection.
Heart Lung Circ
; 31(6): 882-888, 2022 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-35074261
6.
Generation of Dual functional Nanobody-Nanoluciferase Fusion and its potential in Bioluminescence Enzyme Immunoassay for trace Glypican-3 in Serum.
Sens Actuators B Chem
; 3362021 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35250176
7.
HOXC10 promotes cell migration, invasion, and tumor growth in gastric carcinoma cells through upregulating proinflammatory cytokines.
J Cell Physiol
; 235(4): 3579-3591, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31552684
8.
Long non-coding RNA CYTOR enhances gastric carcinoma proliferation, migration and invasion via the miR-136-5p/HOXC10 axis.
Am J Cancer Res
; 13(6): 2714-2731, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37424812
9.
Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC.
Nat Cancer
; 4(6): 860-871, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37322367
10.
Central nervous system efficacy of rezivertinib (BPI-7711) in advanced NSCLC patients with EGFR T790M mutation: A pooled analysis of two clinical studies.
Lung Cancer
; 180: 107194, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37163774
11.
LINC00511/hsa-miR-573 axis-mediated high expression of Gasdermin C associates with dismal prognosis and tumor immune infiltration of breast cancer.
Sci Rep
; 12(1): 14788, 2022 08 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-36042287
12.
Efficacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/Recurrent EGFR T790M-Mutated NSCLC: A Phase 2b Study.
J Thorac Oncol
; 17(11): 1306-1317, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36049654
13.
Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study.
Lancet Respir Med
; 9(8): 829-839, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33780662
14.
MACC1 regulates PDL1 expression and tumor immunity through the c-Met/AKT/mTOR pathway in gastric cancer cells.
Cancer Med
; 8(16): 7044-7054, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31557409
15.
Author Correction: Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC.
Nat Cancer
; 5(1): 209, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38182915
Resultados
1 -
15
de 15
1
Próxima >
>>